

SYMBOLS AND ABBREVIATIONS

MN	Miconazole nitrate
5-FU	5-fluorouracil
SVF	Simulated vaginal fluid
mg	Milligram
gm	Gram
L	Litre
SD	Standard deviation
$t_{1/2}$	Half life
UV	Ultraviolet
%	Percent / percentage
μg	Microgram
Conc	Concentration
FTIR	Fourier transform infrared spectroscopy
DSC	Differential scanning calorimetry
XRD	X-ray diffraction
w/w	Weight/weight
h	Hours
θ	Theta
$^{\circ}\text{C}$	Degree centigrade
λ_{max}	Absorption maxima
rpm	Rotations per minute
RH	Relative humidity

LIST OF TABLES

Table No.	Title	Page No.
1	Calibration curve data of MN in phosphate buffer pH 6.8	76
2	Calibration curve data of MN in SVF pH 4.2	78
3	Calibration curve data of 5-FU in Phosphate buffer pH 6.8	80
4	Calibration curve data of 5-FU in SVF pH 4.2	82
5	Calibration curve data of 5-FU in phosphate buffer pH 7.4	84
6	Formulation chart for MN matrix tablets using chitosan-carbopol 71G IPEC	89
7	Formulation chart for MN matrix tablets using chitosan-CMT IPEC	91
8	Formulation chart for 5-FU matrix tablets using chitosan-polycarbophil IPEC	93
9	Formulation chart for 5-FU matrix tablets using chitosan-sodium alginate IPEC	95
10	Maximum percentage deviation allowed as per IP	97
11	FT-IR spectra data of MN and the formulation	106
12	Evaluation data of MN matrix tablets	119
13	Swelling index data of MN formulations MA1-ME4 in phosphate buffer pH 6.8	122
14	Swelling data of MN formulations MA1-ME4 in SVF pH 4.2	124
15	<i>In vitro</i> dissolution data of MN formulations MA1-ME4 in phosphate buffer pH 6.8	128
16	<i>In vitro</i> dissolution data of MN formulations MA1-ME4 in SVF pH 4.2	131
17	Mucoadhesive strength data for MD1-ME4 formulations	134
18	Mathematical model fitting data for formulations MD1 to ME4	137
19	Stability studies data of ME4 formulation	138
20	FT-IR spectra data of MN and the formulation	142

21	Evaluation data of MN matrix tablets	151
22	Swelling index data of MN formulations MF1-MI4 in phosphate buffer pH 6.8	155
23	Swelling index data of MN formulations MF1-MI4 in SVF pH 4.2	157
24	<i>In vitro</i> dissolution data of MN formulations MF1-MI4 in phosphate buffer pH 6.8	162
25	<i>In vitro</i> dissolution data of MN formulations MF1-MI4 in SVF pH 4.2	164
26	Mucoadhesive strength data for MH1-MI4 formulations	167
27	Mathematical model fitting data for formulations MH1-MH4	169
28	Stability studies data of MI3 formulation	170
29	FT-IR spectra data of 5-FU and the formulation	174
30	Evaluation data of 5-FU matrix tablets	185
31	Swelling index data of 5-FU formulations FA1-FE2 in phosphate buffer pH 6.8	188
32	Swelling index data of 5-FU formulations FA1-FE2 in SVF pH 4.2	190
33	Swelling index data of 5-FU formulations FA1-FE2 in phosphate buffer pH 7.4	192
34	<i>In vitro</i> dissolution data of 5-FU formulations FA1-FE2 in phosphate buffer pH 6.8	197
35	<i>In vitro</i> dissolution data of 5-FU formulations FA1-FE2 in SVF pH 4.2	199
36	<i>In vitro</i> dissolution data of 5-FU formulations FA1-FE2 in phosphate buffer pH 7.4	201
37	Similarity factor (f_2) values calculated for the dissolution profiles of FD4 formulation between different buffer solutions	203
38	Mucoadhesive strength data for FC1-FE2 formulations	204
39	5-FU permeation data for FE1 and FE2 formulations	207
40	Mathematical model fitting data for FC1 to FD2 formulations	208
41	Stability studies data for FE2 formulation	209

42	FT-IR spectra data of 5-FU and the formulation	213
43	Evaluation data of 5-FU matrix tablets	225
44	Swelling index data of 5-FU formulations FF1-FJ2 in phosphate buffer pH 6.8	229
45	Swelling index data of 5-FU formulations FF1-FJ2 in SVF pH 4.2	231
46	Swelling index data of 5-FU formulations FF1-FJ2 in phosphate buffer pH 7.4	233
47	<i>In vitro</i> dissolution data of 5-FU formulations FF1-FJ2 in phosphate buffer pH 6.8	238
48	<i>In vitro</i> dissolution data of 5-FU formulations FF1-FJ2 in SVF pH 4.2	240
49	<i>In vitro</i> dissolution data of 5-FU formulations FF1-FJ2 in phosphate buffer pH 7.4	242
50	Similarity factor (f_2) values calculated for the dissolution profiles of FI2 formulation between different buffer solutions	244
51	Mucoadhesive studies data for FH1-FJ2 formulations	246
52	5-FU permeation data for formulations FJ1 and FJ2	250
53	Mathematical model fitting data for FH1 to FI2 formulations	251
54	Stability studies of formulation FJ2	252

LIST OF FIGURES

Figure No.	Title	Page No.
1	Structure of oral cavity	15
2	Structure of oral mucosa	16
3	Schematic representation of vaginal wall	27
4	Structure of Miconazole nitrate (MN)	58
5	Structure of 5-fluorouracil (5-FU)	59
6	Structure of chitosan	61
7	Structure of sodium alginate	65
8	Structure of Microcrystalline cellulose	66
9	Structure of Sodium deoxycholate	69
10	UV spectrum of MN in phosphate buffer pH 6.8	75
11	Calibration curve of MN in phosphate buffer pH 6.8	76
12	UV spectrum of MN in SVF pH 4.2	77
13	Calibration curve of MN in SVF pH 4.2	78
14	UV spectrum of 5-FU in phosphate buffer pH 6.8	79
15	Calibration curve of 5-FU in phosphate buffer pH 6.8	80
16	UV spectrum of 5-FU in SVF pH 4.2	81
17	Calibration curve of 5-FU in SVF pH 4.2	82
18	UV spectrum of 5-FU in phosphate buffer pH 7.4	83
19	Calibration curve of 5-FU in phosphate buffer pH 7.4	84
20	Schematic representation of formulation design	87
21	Modified physical balance for mucoadhesive studies	100
22	DSC thermogram of MN	104

23	DSC thermogram of MN with excipients	104
24	FT-IR spectra of MN	105
25	FT-IR spectra of MN with excipients	106
26	Effect of ratio of carbopol 71G and chitosan on the transmittance of the solution	108
27	FT-IR spectra of chitosan in 2000-1000 cm^{-1}	109
28	FT-IR spectra of chitosan in 1800-1400 cm^{-1}	110
29	FT-IR spectra of carbopol 71G in 2000-1000 cm^{-1}	111
30	FT-IR spectra of carbopol 71G in 1800-1400 cm^{-1}	111
31	FT-IR spectra of chitosan-carbopol 71G IPEC in 2000-1000 cm^{-1}	112
32	FT-IR spectra of chitosan-carbopol 71G IPEC in 1800-1400 cm^{-1}	113
33	DSC thermogram of chitosan	114
34	DSC thermogram of carbopol 71G	115
35	DSC thermogram of chitosan-carbopol 71G IPEC	116
36	X-ray diffraction spectra of chitosan	117
37	X-ray diffraction spectra of carbopol 71G	117
38	X-ray diffraction spectra chitosan-carbopol 71G IPEC	118
39A	Swelling index profiles for MN formulations MA1-MD3 in phosphate buffer pH 6.8	123
39B	Swelling index profiles for MN formulations MD4-ME4 in phosphate buffer pH 6.8	123
40A	Swelling index profiles for MN formulations MA1-MD3 in SVF pH 4.2	125
40B	Swelling index profiles for MN formulations MD4-ME4 in SVF pH 4.2	125
41A	MN release profile of formulations MA1-MD3 in phosphate	129

	buffer pH 6.8	
41B	MN release profile of formulations MD4-ME4 in phosphate buffer pH 6.8	129
42A	MN release profile of formulations MA1-MD3 in SVF pH 4.2	132
42B	MN release profile of formulations MD4-ME4 in SVF pH 4.2	132
43	Mucoadhesive strength of formulations MD1-ME4	135
44	X-ray radiographic images of buccal and vaginal cavity at 1 and 8 h after ingestion of BaSO ₄ -loaded optimized ME4 matrix tablet in rabbits	136
45	DSC thermogram of MN	139
46	DSC thermogram of MN with excipients	140
47	FT-IR Spectra of pure MN	141
48	FT- IR Spectra of MN with excipients.	141
49	Viscosity of the supernatant solutions of different ratios of chitosan and CMT	143
50	FT-IR spectra of CMT in 2000-1000 cm ⁻¹	144
51	FT-IR spectra of CMT in 1800-1400 cm ⁻¹	145
52	FT-IR spectra of chitosan-CMT IPEC in 2000-1000 cm ⁻¹	146
53	FT-IR spectra of chitosan-CMT IPEC in 1800-1400 cm ⁻¹	146
54	DSC thermogram of CMT	147
55	DSC thermogram of chitosan-CMT IPEC	148
56	X-ray diffraction spectra of CMT	149
57	X-ray diffraction spectra of chitosan-CMT IPEC	150
58A	Swelling index profile for MN formulations MF1-MH4 in phosphate buffer pH 6.8	156
58B	Swelling index profile for MN formulations MI1-MI4 in phosphate buffer pH 6.8	156

59A	Swelling index profile for MN formulations MF1-MH4 in SVF pH 4.2	158
59B	Swelling index profile for MN formulations MI1-MI4 in SVF pH 4.2	158
60A	MN release profile of formulations MF1-MH4 in phosphate buffer pH 6.8	163
60B	MN release profile of formulations MI1-MI4 in phosphate buffer pH 6.8	163
61A	MN release profile of formulations MF1-MH4 in SVF pH 4.2	165
61B	MN release profile of formulations MI1-MI4 in SVF pH 4.2	165
62	Mucoadhesive strength profile of formulations MH1-MI4	167
63	X-ray radiographic images of buccal and vaginal cavity at 1 and 8 h after ingestion of BaSO ₄ -loaded optimized MI3 matrix tablet in rabbits	168
64	DSC thermogram of 5-FU	172
65	DSC thermogram of 5-FU with excipients	172
66	FT-IR Spectra of pure 5-FU	173
67	FT-IR Spectra of 5-FU with excipients	174
68	Transmittance of the supernatant solutions of different ratios of chitosan and polycarbophil	175
69	FT-IR spectra of polycarbophil in 2000-1000 cm ⁻¹	177
70	FT-IR spectra of polycarbophil in 1800-1400 cm ⁻¹	177
71	FT-IR spectra of chitosan-polycarbophil IPEC in 2000-1000 cm ⁻¹	179
72	FT-IR spectra of chitosan-polycarbophil IPEC in 1800-1400 cm ⁻¹	179
73	DSC thermogram of polycarbophil	180
74	DSC thermogram of chitosan-polycarbophil IPEC	181
75	X-ray diffraction spectra of polycarbophil	182

76	X-ray diffraction spectra of chitosan-polycarbophil IPEC	183
77A	Swelling index profile for 5-FU formulations FA1-FC2 in phosphate buffer pH 6.8	189
77B	Swelling index profile for 5-FU formulations FD1-FE2 in phosphate buffer pH 6.8	189
78A	Swelling index profile for 5-FU formulations FA1-FC2 in SVF pH 4.2	191
78B	Swelling index profile for 5-FU formulations FC3-FE2 in SVF pH 4.2	191
79A	Swelling index profile for 5-FU formulations FA1-FC2 in phosphate buffer pH 7.4	193
79B	Swelling index profile for 5-FU formulations FC3-FE2 in phosphate buffer pH 7.4	193
80A	5-FU release profile of FA1-FC2 formulations in phosphate buffer pH 6.8	198
80B	5-FU release profile of FC3-FE2 formulations in phosphate buffer pH 6.8	198
81A	5-FU release profile of FA1-FC2 formulations in SVF pH 4.2	200
81B	5-FU release profile of FC3-FE2 formulations in SVF pH 4.2	200
82A	FU release profile of FA1-FC2 formulations in phosphate buffer pH 7.4	202
82B	5-FU release profile of FC3-FE2 formulations in phosphate buffer pH 7.4	202
83	Mucoadhesive strength profile for FC1-FE2 formulations	204
84	X-ray radiographic images of buccal, vaginal and rectal cavity at 1 and 8 h after ingestion of BaSO ₄ -loaded optimized FE2 matrix tablet in rabbits	205
85	5-FU permeation profiles of FE1 and FE2 formulations	207
86	DSC thermogram of 5-FU	210
87	DSC thermogram of 5-FU with excipients	211

88	FT-IR Spectra of pure 5-FU	212
89	FT-IR Spectra of 5-FU with excipients.	212
90	Viscosity measurement of the supernatant solutions of different ratios of chitosan and sodium alginate	214
91	FT-IR spectra of sodium alginate in 2000-1000 cm^{-1}	215
92	FT-IR spectra of sodium alginate in 1800-1400 cm^{-1}	216
93	FT-IR spectra of chitosan-sodium alginate IPEC in 2000-1000 cm^{-1}	217
94	FTIR spectra of chitosan-sodium alginate IPEC in 1800-1400 cm^{-1}	217
95	DSC thermogram of sodium alginate	219
96	DSC thermogram of chitosan-sodium alginate physical mixture	220
97	DSC thermogram of chitosan sodium alginate IPEC	221
98	X-ray diffraction spectra of sodium alginate	222
99	X-ray diffraction spectra of chitosan-sodium alginate IPEC	223
100A	Swelling index profile 5-FU for formulations FF1-FH2 in phosphate buffer pH 6.8	230
100B	Swelling index profile for 5-FU formulations FH3-FJ2 in phosphate buffer pH 6.8	230
101A	Swelling index profile for 5-FU formulations FF1-FH2 in SVF pH 4.2	232
101B	Swelling index profile for 5-FU formulations FH3-FJ2 in SVF pH 4.2	232
102A	Swelling index profile for 5-FU formulations FF1-FH2 in phosphate buffer pH 7.4	234
102B	Swelling index profile for 5-FU formulations FH3-FJ2 in phosphate buffer pH 7.4	234
103A	5-FU release profile of formulations FF1-FH2 in phosphate buffer pH 6.8	239

103B	5-FU release profile of formulations FH3-FJ2 in phosphate buffer pH 6.8	239
104A	5-FU release profile of formulations FF1-FH2 in SVF pH 4.2	241
104B	5-FU release profile of formulations FH3-FJ2 in SVF pH 4.2	241
105A	5-FU release profile of formulations FF1-FH2 in phosphate buffer pH 7.4	243
105B	5-FU release profile of formulations FH3-FJ2 in phosphate buffer pH 7.4	243
106	Mucoadhesive strength profile for formulations FH1-FJ2	246
107	X-ray radiographic images of buccal, vaginal and rectal cavity at 1 and 8 h after ingestion of BaSO ₄ -loaded optimized FI2 matrix tablet in rabbits	248
108	5- FU permeation profiles of FJ1 and FJ2 formulations	250